FDMT
4D Molecular Therapeutics In
NASDAQ · Biotechnology
$8.99
+0.60 (+7.15%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 35.7K | 280.9K | 256.30M | 228.58M | 262.66M |
| Net Income | -152,110,585 | -1,077,100,916 | -65,224,635 | -57,732,834 | -71,516,444 |
| EPS | — | — | — | — | — |
| Profit Margin | -434,778.4% | -413,039.5% | -25.5% | -25.3% | -27.2% |
| Rev Growth | -87.3% | -87.3% | +0.0% | +10.3% | +10.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 25.89M | 29.62M | 33.00M |
| Total Equity | — | — | 233.21M | 238.80M | 269.31M |
| D/E Ratio | — | — | 0.11 | 0.12 | 0.12 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -173,289,055 | -1,295,236,839 | -118,507,398 | -107,016,126 | -112,376,502 |
| Free Cash Flow | — | — | -99,529,069 | -89,291,698 | -82,297,413 |